Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18587049 | 1.00 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL787013 | 1.00 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL18587048 | 1.00 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL19911651 | 1.00 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL5973186 | 1.00 | GSR (0.34) | GSRALDH1A1 | |
| SCHEMBL3196473 | 0.96 | GSR (0.38) | GSRALDH1A1 | |
| SCHEMBL5974111 | 0.94 | GSR (0.40) | GSRALDH1A1 | |
| SCHEMBL789543 | 0.87 | — | — | |
| SCHEMBL789664 | 0.87 | — | — | |
| SCHEMBL18094442 | 0.84 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2020-08-27 | — | — | US | disclosed |
| US-10442792-B2 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ABBVIE INC. | 2018-03-01 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809576-B1 | Synthetic route to anti-viral agents | ABBVIE INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2618831-B1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220748-B2 | Macrocyclic proline derived HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2015-06-25 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012040167-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263860-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | GSR 2059/4885ALDH1A1 1434/4885 |
| US-20120070416-A1 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors | PREP, PRSS1, PEPD | GSR 2059/4885ALDH1A1 1434/4885 |
| US-20200270303-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | GSR 2059/4885ALDH1A1 1434/4885 |
| US-10442792-B2 | Synthetic route to anti-viral agents | ACE, ACE2, PREP | GSR 3396/4885ALDH1A1 4400/4885 |
| US-20150175655-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GSR 1030/4885ALDH1A1 125/4885 |
| US-20180057482-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | GSR 3396/4885ALDH1A1 4400/4885 |
| US-20140194350-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | GSR 2059/4885ALDH1A1 1434/4885 |
| US-20190084966-A1 | SYNTHETIC ROUTE TO ANTI-VIRAL AGENTS | ACE, ACE2, PREP | GSR 3396/4885ALDH1A1 4400/4885 |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | PREP, PRSS1, PEPD | GSR 2059/4885ALDH1A1 1434/4885 |
| US-20140017198-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | GSR 902/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.